HUBB vs LYEL · P/E 28, rev $5.84B vs rev $6.0K
Hubbell Inc (HUBB) versus Lyell Immunopharma Inc (LYEL) — a side-by-side from cached financials, not a winner call.
Hubbell Inc (HUBB) is a electrical equipment & parts company listed on US.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Latest reported HUBB revenue for 2025-12-31 was $5.84B. Net income was $887.1M. Revenue was up 3.8% from 2024-12-31 to 2025-12-31. HUBB currently screens at market cap $22.14B and trailing P/E 28.0.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
HUBB currently screens at market cap $22.14B and trailing P/E 28.0. LYEL currently screens at market cap $143.5M.
Not investment advice. Open the HUBB and LYEL stock pages for the full models.
Not investment advice.